Tuesday, June 27, 2017 11:17:13 PM
From: Rebecca Wilson <rwilson@buchanwe.com.au>
Dear ***********
The Board and Management has put in place a rapid sub-analysis of the data that will be completed within 4-6 weeks and will require very little funds to undertake. This will ensure that any individual and sub group signals are identified, if they exist. The Board is acutely aware that shareholders will be looking for guidance and post this analysis they will provide an update on the outcome of that review, what this means to the company, and the next steps.
The company currently has $3.75M in the cash and is expecting a R&D tax rebate of approx.. $1.4M. Rest assured they will be very prudent with these funds to ensure the Board is in a position to make the right decisions for shareholders.
With thanks
Rebecca
$INNMF
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM